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Abstract:  The term neurodegenerative disorders, encompasses a variety of underlying 
conditions, sporadic and/or familial and are characterized by the persistent loss of neuronal 
subtypes. These disorders can disrupt molecular pathways, synapses, neuronal 
subpopulations and local circuits in specific brain regions, as well as higher-order neural 
networks. Abnormal network activities may result in a vicious cycle, further impairing the 
integrity and functions of neurons and synapses, for example, through aberrant excitation 
or inhibition. The most common neurodegenerative disorders are Alzheimer’s disease, 
Parkinson’s disease, Amyotrophic Lateral Sclerosis and Huntington’s disease. The 
molecular features of these disorders have been extensively researched and various unique 
neurotherapeutic interventions have been developed. However, there is an enormous 
coercion to integrate the existing knowledge in order to intensify the reliability with which 
neurodegenerative disorders can be diagnosed and treated. The objective of this review 
article is therefore to assimilate these disorders’ in terms of their neuropathology, 
neurogenetics, etiology, trends in pharmacological treatment, clinical management, and the 
use of innovative neurotherapeutic interventions. 
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1. Introduction 
 
Disorders that are associated with atrophy of the central nervous system (CNS) structures are 
termed neurodegenerative disorders (NDs) with the most common of these disorders being 
Alzheimer’s disease (AD), Parkinson’s disease (PD), Amyotrophic Lateral Sclerosis (ALS) and 
Huntington’s disease (HD). The prevalence of NDs is increasing rapidly
 despite extensive research in 
the field [1]. The disorders are both sporadic and familial and affect distinct zones of the brain, causing 
motor and/or cognitive difficulties such as aphasia, apraxia and agnosia that consequently disrupt the 
personality, intellect, social and occupational function of patients [2-6].  
Due to an overlap in the neuropathological symptoms of common NDs a fundamental challenge is 
the identification of genetic patterns and symptoms that reveal the type of disorder whilst the patient is 
still alive. These uncertainties often lead to misdiagnosis and subsequent erroneous therapy. The 
rapidly growing insights into the genetic and molecular mechanisms underlying NDs need to be 
detailed to ensure superior diagnostic strategies and to aid in exchanging knowledge between scientists 
and health professionals. Evaluation of prevalent genetic mutations facilitates the identification of 
genetic markers that may be associated with NDs. Research conducted on various animal models and 
human epidemiological studies demonstrated clear evidence verifying that genetic and environmental 
factors may lead to an increased risk of neurodegeneration [7-9]. Some NDs are characterized by 
neuronal and glial accumulations (since inclusions are mainly deposited in astroglia) [10-14]. 
Tauopathies associated with NDs have several commonalities at the molecular level and many are 
characterized by age-dependent abnormal accumulation of misfolded proteins that aggregate into 
fibrillar deposits with amyloid. The extent of neurodegeneration depends on the area and magnitude of 
protein aggregation. Aggregation of abnormal proteins both inside and outside cells is a prominent 
feature of common disorders such as AD and PD [15]. Similarly, synucleinopathies, e.g. PD, are 
characterized by aggregation of α-synuclein and, occasionally, gene mutations (Figure 1).  
Although NDs are associated with progressive neuronal loss, a few neurological impairments may 
reflect network dysfunction rather than a loss of neurons [17-19]. Patients in particular with AD or 
other NDs display remarkable fluctuations in neurological function even during the same day. These 
fluctuations most likely reflect variations in neural network activity such as chronic intoxication by 
abnormal proteins that the brain is temporarily able to overcome [20,21]. Thus far, abnormal protein 
aggregation have shown to trigger cycles of aberrant neuronal activity and compensatory alterations in 
neurotransmitter receptors with related signaling pathways that lead to synaptic deficits, disintegration 
of neural networks, and ultimately failure of neurological function [21]. In vivo studies in animal 
models have shown that few pathogenic cascades can be prevented or reversed by removing abnormal 
proteins or pharmacologically modulating neuronal activity without precipitating effects on neuronal 
number [22]. Enhancing neuronal plasticity may help functional neural circuits to compensate for non-Int. J. Mol. Sci. 2009, 10                 
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functional circuits and improve the overall network performance and neurological function [20,23,24] 
Furthermore, apoptosis involvement in NDs has been detected in autopsies of human brain tissue as 
well as in in vivo animal models [25,26]. Understanding the central role of cascades during apoptosis 
has led to the development of several inhibitory neuroactive drugs. Post-mortem investigations   
have enlightened researchers on the microglia-produced inflammatory and neurotoxic factors such  
as cytokines and tumor necrosis factor-α (TNFα) that have free radicals which are deleterious to 
neurons [27]. 
Figure 1. Schematic diagram outlining the pathogenesis of common neurodegenerative 
diseases (Adapted from Yuan and Yanker, [16]). 
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Developing new diagnostic and treatment modalities for NDs is an active area of research that 
attempts to evaluate current therapeutic interventions towards restoring neurochemical balances in the 
brain or slowing the progression of NDs [28-31]. The few neuroactive drugs that are currently 
approved by the US Food and Drug Administration (FDA) have demonstrated only modest effects in 
modifying the symptoms of NDs for relatively short periods of time in subsets of patients, and none 
has shown an effect on halting the progression of NDs. Pharmaceutical researchers are confronting 
past failures, and therefore tissue transplantation and stem cell research are currently a major area of 
investigation. Mobilizing endogenous neuronal stem cell populations to repair damaged tissue and 
potentially stimulate reformation of damaged synapses is being explored [32-34]. A discerning fact on 
neurotherapeutics is the constraint of the Blood-Brain Barrier (BBB) and the drug release kinetics that 
cause increased side-effects. The vascular endothelial cells, choroid plexus and the arachnoid 
membrane act together to form a barrier between the blood and cerebrospinal fluid to efficiently 
prevent neuroactive agents from entering the brain. More in depth exploration of the BBB would aid in 
the design of techniques to manipulate the BBB and transport neuroactive agents into the brain.  
This review paper attempts to identify and assimilate the key molecular features of common NDs 
and the associated mutated protein inclusions in the degenerating cells and the surrounding viable 
neurons. AD, PD, ALS and HD are extremely complex and common NDs and have been selected for Int. J. Mol. Sci. 2009, 10                 
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review in this paper. Their etiology is frequently unknown, however severe genetic mutations that lead 
to misfolding and aggregation in extracellular protein depositions coupled with neuronal network 
dysfunction have been observed in NDs. Currently, there are no completely effective neurotherapeutic 
interventions that have been developed. Research findings that implicate the commonalities in protein 
aggregations could insinuate that a few NDs may share a common or overlapping neuropathogenic 
mechanism(s) which could be targeted by synchronized neurotherapeutic strategies. Therefore, in 
addition this review paper provides a concise incursion into the neurotherapeutic modalities directed to 
CNS drug delivery that may be useful in overcoming many of the therapeutic challenges of NDs. To 
meet this end, the neuropathology and genetics of common NDs, the current neurotherapeutic trends of 
NDs, the possible novel biomarkers that can be used to identify the debilitating symptoms of 
neurodegeneration, and recent directions in research and clinical trials are also discussed. 
 
2. General Underlying Mechanisms Resulting in Neurodegeneration 
 
2.1. Network dysfunction 
 
Due to the fact that the progressive neurological decline observed in NDs is associated with 
neuronal loss, the peak performance of patients at any disease stage may be capped by the loss of 
neurons. However, the extent to which neurological deficits in NDs relate directly to neuronal loss is 
controversial
 [17,18,22-24]. Furthermore, processes that do not involve significant neuronal loss
 may 
cause similar functional impairments. Thus, it is unlikely that changes in neuronal number may 
account for the rapid and reversible fluctuations in neurological function. Such fluctuations probably 
reflect complex adjustments in molecules, signaling cascades, synaptic modifications, neuronal 
activities and network interactions. It has been established that transgenic mouse models expressing 
abnormal proteins develop distinct disease-related neurological impairments [21]. In transgenic mice, 
the elimination of abnormal proteins may reverse neurological deficits without changing neuronal 
number [35]. Thus, neurological impairments that are associated with NDs may be caused by neuronal 
dysfunction rather than neuronal loss. This concept is supported by the fact that effective neural 
plasticity allows the brain to cope even with striking neuronal losses [36]. 
 
2.2. Synaptic dysfunction leading to network failure 
 
Neural plasticity is highly adaptive during healthy and disease states. This enables individuals to 
interact effectively with their environment and to cope with neural injuries. A major component of 
neural plasticity is found in synapses, which are actively strengthened and weakened by complex 
processes to form the dynamic neural circuits and higher-order networks that store memories, give rise 
to thoughts and create the awareness of an individual. Notably, abnormal proteins that are suspected of 
causing NDs impair the integrity or function of pre-synaptic terminals and post-synaptic 
specializations [37].  Numerous mechanisms may be involved, including excitotoxicity [38], 
inflammation [39],  oxidative stress [40]  and other processes [41-43]. In AD synaptic loss exceeds 
neuronal loss, and depletion of synapses and synaptic proteins correlates with cognitive decline than 
does the abundance of plaques or tangles [43].  Chronic alterations in synaptic plasticity and Int. J. Mol. Sci. 2009, 10                 
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neurotransmission may affect activity-dependent signaling and gene expression, resulting in the 
disintegration of neural networks which ultimately leads to the failure of neural function. Conversely, 
environmental stimulation has shown to increase synaptic plasticity that may delay and decrease 
pathological alterations [44]. Furthermore, diverse neural injuries elicit effective plasticity responses 
with the protective apo-E2 and apo-E3 isoforms, but not with apo-E4 which increases the risk and 
accelerates the onset of AD and PD [45]. 
 
2.3. Survival of neurons 
 
There are numerous factors that may influence the survival of neurons at different stages of NDs. 
These include the functional state of neurons in affected areas [46,47], the ability of people to use 
specific learning strategies to overcome deficits [48,49], genetic factors such as apo-E isoforms [45] 
and co-morbidities such as vascular disease [50]. In addition, alternative neural networks may 
compensate for the lost neurons [47,48]. However, such compensation of neuronal dysfunction does 
not directly influence the survival of neurons, but rather the phenotype. The prototypic elements of the 
Fibroblast Growth Factor (FGF) family, FGF1 and FGF2, have been implicated
  in various 
physiological and pathological processes. FGF1 and FGF2 have been ubiquitously expressed however 
are not efficiently secreted. Gene knockouts in the mice model have previously
 demonstrated a role for 
FGF2 in brain development. Studies of mice lacking individual FGFs revealed a variety of phenotypes 
that ranged from early embryonic lethality to mild defects These findings most likely reflect the 
redundancy of the FGF family of ligands or their uniqueness of expression in specific tissues [51]. The 
relatively mild phenotypic
  defects associated with FGF2 deletion led to the hypothesis that
  the 
continued expression of other FGFs partially compensated for
 the absence of FGF2 in the mice. Miller 
and coworkers, [51], reported the generation
 of mice lacking FGF1 and their use, in combination with 
a previously
 described FGF2 null mouse, to produce mice that lack both FGF1 and
 FGF2. FGF1-FGF2 
double-knockout mice were found to be viable and fertile and
 did not display any gross phenotypic 
defects. In the double-knockout
  mice they observed defects that were similar in extent to those
 
previously described for the FGF2 null mice. In addition, differences in the
 organization of neurons of 
the frontal motor cortex were observed and no
 abnormalities were found in mice lacking only FGF1. 
Their results
  suggested that the relatively mild defects in FGF2 knockout animals
  were not a 
consequence of compensation by FGF1 and suggested highly
 restricted roles for both factors under 
normal neuronal developmental and
 physiological
 conditions [52-55]. 
Most modulators represent potential targets for therapeutic intervention. Studies have shown that in 
the absence of disease, neural systems are characterized by extensive degeneracy i.e. the ability of 
structurally different elements to perform the same function or yield the same output [56-58]. This 
degeneracy may serve to explain the fact that neurons in the substantia nigra may become non-
functional before they are missed at the clinical level and cause NDs to progress at a gradual pace. The 
complexity of compensatory mechanisms has been demonstrated by the multi-level adjustments that 
can occur in the cortical–basal-ganglia–thalamocortical network at different stages of PD and in 
related animal models [59]. Notably, progressive failure of these compensatory mechanisms may be 
the contributing factors to the prominent daily fluctuations in the effectiveness of levodopa which is 
often referred to as “the on–off phenomenon” in advanced PD treatment. Therefore, tremendous Int. J. Mol. Sci. 2009, 10                 
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benefits may be reaped from neurotherapeutic interventions that maximize the patient's opportunity for 
optimal performance by shifting the focus from neurons that are lost to those that survive [60]. In 
addition, several studies reporting the survival, integration and function of stem cell grafts in animal 
models of HD have been reported [61-63]. The majority of these studies have been based on 
transplantation of fetal neural progenitors, expanded as neurospheres and differentiated in vitro prior to 
transplantation [64].  
 
3. Overview of Alzheimer’s Disease  
 
Alzheimer’s disease (AD) is recognized as the most common form of dementia affecting an 
estimate of 24 million people worldwide, 40% of them living in less developed countries [65]. The 
prevalence of dementia in Western Europe is about 4.5 million, and its total annual costs amount to 55 
billion Euros [65-67]. As a consequence of rapid demographic ageing, AD has become one of the most 
severe progressive socio-economical and medical burdens facing countries in the next century. AD can 
be classified into early onset (< 65 years) and late onset (> 65 years) forms [68]. Sporadic AD is the 
most common form of both early- and late-onset AD. It is considered to be a result of complex genetic 
and environmental risk factors. AD is characterized by a progressive decline in cognitive function, loss 
of memory, and other neuro-behavioural symptoms. The progressive neurodegeneration occurs in 
multiple areas of the brain, including the nuclei basalis, hippocampus, amygdale, and entorhinal 
cortex. Although the etiology of AD is unknown and the pathophysiological processes that underlie the 
steady progression of the clinical course are not clearly understood, it is apparent, that mechanisms of 
cell-to-cell communication are disrupted. Genetic factors may also play a substantial role in the 
etiology of adult-onset
 AD [69].  
There is no laboratory test for the diagnosis of AD. The diagnosis of AD is primarily based on 
clinical and neuropsychological observations with the simultaneous exclusion of other possible causes 
for dementia. The most commonly used clinical criteria were outlined previously by the National 
Institute of Neurological and Communicative Disorders and Stroke and Alzheimer’s Disease and 
Related Disorders Association (NINCDS-ADRDA) [70]. According to NINCDS-ADRDA, the 
diagnosis of AD may be confirmed by neuropathological examination at either biopsy or autopsy using 
biological markers (neuro-imaging). The diagnosis made by the NINCDS-ADRDA has high accuracy 
(80 – 90%) according to data obtained from patients with severe AD and repeated examinations 
[71,72]. However, the accuracy is acknowledged to be lower when diagnosing patients with early 
stages of AD or with mild cognitive impairment (MCI), and in the absence of repeated   
examinations [73]. 
The clinical diagnosis of AD is currently based on progressive memory impairment and decline in 
at least one other cognitive domain, and by excluding other diseases such as frontotemporal dementia, 
dementia with Lewy-bodies (DLB), stroke, brain tumor, normal pressure hydrocephalus or depression, 
that might also present with dementia [74,75]. The clinical diagnostic accuracy for AD depends on the 
stage of disease and can exceed 90% [76]. Diagnostic criteria for AD have been proposed within both 
the Diagnostic and Statistical Manual (DSM) [77] and International Classification of Diseases (ICD) 
classification systems [78]. However, the criteria followed in most research studies are those proposed 
by the NINCDS-ARDA for defining probable AD [70]. A variable period of prodromal decline in Int. J. Mol. Sci. 2009, 10                 
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cognition of up to five years usually precedes the formal diagnosis of AD. This stage, known as 
Minimal Cognitive Impairment (MCI), is characterized by a relatively isolated impairment in long 
term memory and may also be accompanied by impairments of working memory. These deficits 
presumably relate to damage to the medial temporal lobe and/or specific prefrontal–temporal lobe 
circuits. Approximately 40 – 60% of subjects with MCI will subsequently progress to meet criteria for 
AD over a 3-4-year period [79-81].  
AD is a pathologically complex and etiologically a multi-factorial disease. There are a few 
causative genes which have been linked to the relatively small proportion of patients with early-onset 
familiar AD. In addition, numerous other genetic risk factors predisposing for AD have been identified 
[82]. However, it has become evident that genes alone cannot explain the late-onset sporadic AD. 
Numerous environmental factors also contribute significantly to the development of AD. In the last 
decade significant progress has been made in elucidating the resulting changes of single-gene defects 
in familial forms of AD [83]. For instance it has been established that a genetic defect that causes a 
severe immune deficiency in humans may also produce balance disorders [84]. Several highly 
penetrant genes have been cloned for rare, autosomal-dominant, early onset forms of AD. The major 
gene defects include mutations in the amyloid precursor protein and presenilins that lead to increased 
amyloid deposit and AD [83]. Gene defects are responsible for approximately 1% of all AD cases and 
currently numerous efforts are being directed to searching for mutations in identified genes with the 
hope that this may provide further insight into the more common sporadic cases of AD [83]. 
 
3.1. The neuropathology of Alzheimer’s disease 
 
Realization of accurate pathophysiology is vital for the development of neuroactive agents that are 
able to cease the β-amyloid (Aβ) peptide aggregation and avert the progression of AD. The 
neuropathological features of AD is the fibrillar aggregates of Aβ peptides in senile plaques and blood 
vessel walls, the formation of neurofibrillary tangles (NFTs), and the loss of neurons, which lead to the 
compromised functioning of the neurotransmitter system. While Aβ peptides are the primary 
components of AD plaques, there have been a few discrepancies on whether the Aβ aggregation is the 
only cause of AD neurotoxicity [85]. On one hand, there is considerable evidence that fibrillar 
aggregation of free, non-polymerized Aβ and amyloid deposition are associated with AD 
neurotoxicity. In addition, there have also been propositions that other neuropathological abnormalities 
such as gliosis, chronic inflammatory reactions, excitotoxic damage and oxidative stress appear to be 
also involved in the neurodegenerative processes occurring in the AD brain [76].  
 
3.1.1. The amyloid hypothesis 
 
The amyloid hypothesis as the primary trigger of AD is supported by the fact that all known 
mutations causing familiar AD target Amyloid Precursor Protein (APP) processing and that plaque 
formation has also been estimated to be a relatively early event in AD brain [86]. The Aβ plaques and 
NFTs are intracellular aggregates of hyperphosphorylated microtubular tau proteins appearing as 
paired and helical filaments [13]. Non-polymerized Aβ peptides insert between lipid bi-layer 
membranes and generate non-selective cation channels that may trigger cellular death. In addition, Int. J. Mol. Sci. 2009, 10                 
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ubiquitin, a protein that generally latches onto mutated proteins tagging them for proteolysis, is found 
in association with NFTs. Consequently the ubiquitinated NFTs are recognized for degradation by 
proteosomes in the brain [86]. The histopathological signs at onset are Aβ plaques which progress to 
the development of NFTs, neuronal reduction and subsequent brain atrophy [85-87]. These changes 
are particularly observed in the hippocampus, substantia innominata, locus cerulueus as well as the 
tempoparietal and frontal cortices of the brain. Further accrued data implicate the neuronal lysosomal 
system as an additional degradative pathway. Mutations of presenilin 1 and 2 have amyloid-
independent effects on the lysosomal system which augment the Aβ plaque [88-91]. In addition to 
brain atrophy and widened sulci, the neurochemical signs are the paucity of neurotransmitters 
including choline acetyltransferase, acetylcholine, noradrenalin, serotonin and somatostatin [92]. 
Changes in neurotransmitter concentrations lead to behavioural changes such as wandering, agitation, 
depression, aggression and delusions. Neuroactive agents capable of impeding the aggregation may be 
potentially useful in preventing or diminishing the toxicity of Aβ peptides. In this regard, recent 
studies have aimed at interfering with amyloid aggregation as a possible route for prevention or 
treatment of AD [13,86]. 
 
3.1.2. The tau hypothesis 
  
Neurofibrillary changes of abnormally hyperphosphorylated tau are the key lesion in AD and a 
number of other tauopathies [93]. The phosphoprotein, tau that is synthesized by neurons is also 
present in astrocytes and oligodendrocytes within the brain, and in peripheral tissues [94,95]. Tau is 
coded by a gene located on chromosome 17 and alternatively spliced into 6 isoforms ranging from 352 
– 441 amino acids in length [96, 97]. Tau is the major microtubule-associated protein that promotes the 
assembly and stability of microtubules, which play vital structural and functional roles in neurons. 
Healthy neurons are internally supported in part by these microtubules that facilitate the transport of 
nutrients and other cellular components from the cell body to the ends of the axon and back of 
neurons. Tau, which normally has phosphate molecules attached, binds to the microtubules and 
stabilizes them. In AD, an abnormally high number of additional phosphate molecules become 
attached to tau. As a result, tau disengages from the microtubules and aggregates forming tangles. The 
microtubules disintegrate and the transport system of the neuron collapses resulting initially in 
malfunctions in communication between neurons and later in neuronal cell death. Tau phosphorylation 
has been suggested to play a key role in AD pathogenesis since it has been shown to correlate with the 
severity of dementia. Braak and Braak, [98,99], proposed a model of pathological evolution of AD. 
According to the model, NFTs appear in the entorhinal cortex during the preclinical phase, spreading 
to the hippocampus in the middle phase and, finally, progressed to the neocortex during the late stages 
of AD [99]. Although scientists are exploring further, currently the etiology of AD still remains a 
challenge [100-104].  
However, the present focus for AD includes endogenous molecules that are associated with Aβ 
peptide production such as the APP, presenilin 1 and 2 genes located on chromosome 21, 14 and 1 
respectively [105,106]. Chemically altered tau proteins instead, aggregate to form disabling tangles 
that injure the nerve cells. Moreover, once microtubules disintegrate the transport system of the 
neurons collapse leading to communication malfunctions between neurons and later also in brain cells. Int. J. Mol. Sci. 2009, 10                 
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The neuron disintegration along with tau-based traffic inhibition may represent the early stages of  
AD [106]. 
 
3.1.3. The role of inflammation 
 
Inflammatory reactions in the CNS are mainly mediated by brain-specific glial cells, notably by 
microglia and astrocytes, and to a lesser degree by neurons. Under physiological conditions, glial cells 
support and protect neurons and their functions, and have numerous critical roles in the homeostasis 
and activity of the brain [107]. In AD, inflammation has recently been confirmed as an essential 
feature, particularly in association with neuritic plaques. The inflammatory reaction is characterized by 
activation of glial cells, gliosis and the appearance of inflammatory proteins such as complement 
factors, acute phase proteins, and pro-inflammatory cytokines [108]. Evidence from autopsy-based 
studies suggests the involvement of microglial activation in the pathogenesis of neurodegeneration by 
the secretion of a variety of pro-inflammatory and neurotoxic factors. These macrophage-like cells 
were found to co-localize with neurotic plaques in the brain and are believed to induce as well as 
exacerbate neurodegeneration [109]. This phenomenon was also supported by clinical trials in which 
non-steroidal anti-inflammatory drugs were demonstrated to reduce the risk of developing AD [110].  
A study revealed that pre-treatment of primary cultures of microglia generated from rapid-autopsy 
brain tissue with indomethacin and anti-Aβ antibody resulted in the efficient opsonization and 
subsequent degradation of Aβ peptides without the concomitant up-regulation of cytokines that are 
typically associated with the activated state [111]. In addition, Rogers and Lahiri, [112] have identified 
inflammation cytokines and biological metal such as copper, zinc and iron as significant factors that 
augment the onset of sporadic late onset forms of AD.  
Ghopade et al. [113] are extensively investigating the proposed activation of glia (astrocytes and 
microglia) by pro-inflammatory cytokines such as IL-1β leading to changes in the immune and neural 
functions of astrocytes during inflammation ultimately contributing to NDs (Figure 2). The acute 
inflammatory response of glia includes enhanced production of tissue inhibitor of metalloproteinase 
(TIMP-1) in the tissue microenvironment that serves as a repair response early in injury. In addition, 
expression of Fas ligand (a type II transmembrane protein that belongs to the TNF family) and down-
regulation of other trophic factors such as brain derived neurotrophic factor (BDNF) during acute 
immune activation of glial cells may also contribute to neurotoxicity. However, under sustained 
inflammatory conditions, such as those observed in chronic NDs, the response of glia may be 
significantly different (i.e. decreased production of TIMP-1). Dhar et al. [114] previously implicated 
the importance of astrocyte production of tissue inhibitor of TIMP-1 in CNS homeostasis and 
inflammatory diseases. The contribution of transforming growth factor (TGF)-signaling in astrocyte-
MMP/TIMP-1-astrocyte regulation was investigated. Co-stimulation of astrocytes with IL-1β and TGF 
mimicked the TIMP-1 down-regulation observed with IL-1β chronic activation. The study proposed 
that one of the mechanisms involved in TIMP-1 down-regulation may be through TGF-signaling in 
chronic immune activation, thus demonstrating a novel extracellular regulatory loop in astrocyte-
TIMP-1 regulation [114]. Int. J. Mol. Sci. 2009, 10                 
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Figure 2. The role of glial cells in central nervous system inflammation and 
neurodegeneration. BDNF = brain-derived neurotrophic factor, MP = macrophages,   
MMP = membrane metalloproteinase, TIMP = tissue inhibitors of metalloproteinase 
(Adapted from: Ghorpade et al. [113]). 
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3.1.4. The role of free radicals 
 
Oxidative damage of biological systems occurs when the production of oxygen radicals and ROS 
exceeds the cell's antioxidant capacity, leading to oxidative imbalance in a system [115,116]. The 
concept of oxidative stress in AD was originally derived from the free radical theory of aging. 
Recently, numerous studies have been published reporting a variety of results on the role of oxidative 
stress in AD [117]. There is evidence of increased oxidation of DNA, RNA, protein, lipids and 
carbohydrates in the AD brain [118]. Thus, the role of free radicals in the pathogenesis of AD has 
become an important area of research over the past two decades. Insufficiency in the functioning of 
mitochondrial cytochrome oxidase, altered iron homeostasis and unbalanced high superoxide 
dismutase activity, have been identified as primary causes of oxidative damage stress in NDs. In 
addition, numerous biochemical conditions have been found to produce free-radical malfunctioning by 
superoxide dismutase. These include mitochondrial cytochrome oxidase insufficiency, unbalanced 
high activity, and an alteration in iron homeostasis, potentially resulting in the production of more 
peroxide. In vitro studies have shown a role played by oxygen-free radicals in promoting amyloid 
aggregation. The presence of Aβ plaques induces the susceptibility of neuronal cultures to oxidative 
toxicity between collaboration of Aβ and oxidative reactive species tend to augment the neuronal 
damage in AD.  Int. J. Mol. Sci. 2009, 10                 
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3.1.5. Excitotoxicity 
 
Excitotoxicity is also considered to play an important role in the pathogenesis of AD. It is triggered 
by excessive stimulation of glutamate receptors (e.g. N-methyl-D-aspartate also known as NMDA) due 
to either increased release or decreased uptake of excitatory amino acids, mostly glutamate [119]. As a 
result, perturbations occur in cellular ion homeostasis (Ca
2+, K
+, Na
+) and metabolic activities. The 
most crucial disturbance is considered to be the overload in the intracellular level of Ca
2+ that may 
originate from the extracellular space and/or ER, resulting in diverse neurotoxic effects due to calcium 
dysregulation and alterations in Ca
2+-signaling pathways [120,121]. Calcium dysregulation may also 
be caused by ER stress, which is characterized by inhibition of protein glycosylation and an increase in 
unfolded proteins in the ER [122,123]. Under pathological conditions, an increase in intracellular 
calcium results in overload of Ca
2+ in mitochondria, causing mitochondrial dysfunction manifested by 
increased production of ROS, decreased energy metabolism, release in cytochrome c, and eventually 
apoptosis [124]. In brain, calcium dysregulation is considered to be capable of eliciting increased Aβ 
formation and tau phosphorylation [125,126]. It must be remembered that calcium dysregulation, ER 
stress, mitochondrial dysfunction, and defective energy metabolism may also be initiated by other 
factors that are unrelated to excitotoxicity. 
 
3.1.6. Other risk factors 
 
Age and family history are significant risk factors. However environmental factors, previous head 
injury and Down’s syndrome cannot be ruled out. Other risk factors include polymorphism in genes 
such as α-microtubulin, apo-E, low density lipoprotein receptor-related protein and very low density 
lipoprotein receptors. While mutations of the PS-1, PS-2,11 and APP genes (resulting in increased 
production and elevated plasma levels of Aβ protein) on chromosomes 1, 14, and 21, respectively, 
have been associated with the rare form of familial AD, the only consistent marker for the late-onset 
non-familial form of AD is the apo-E allele on chromosome 19. The apo-E gene is present in three 
alleles, ε2, ε3, and ε4. The ε4 allele and α2 macroglobulin polymorphism are major risk factors for 
causing AD. This refers specifically to the ε4 allele, though it is absent in approximately 30 – 40% of 
patients with AD and present in approximately 30% of healthy subjects. Conversely, the ε3 allele is 
believed to represent no increased or decreased risk, while the ε2 allele may confer some protection 
[64,127,128]. Increasing evidence also suggests that apoptosis is the major type of cell death involved 
in NDs although inflammation is also involved in the pathogenesis [129-131]. In the CNS, potential 
inducers of apoptosis include neurotrophic factors, changes in potassium concentration, calcium 
dysregulation, modulators of protein phosphorylation, DNA damage, neurotransmitters (glutamate), 
peptides and proteins (Αβ), oxidative stress, nitric oxide, lipids (i.e. retinoic acid), irradiation, as well 
as certain neurotoxins such as ethanol [132]. 
 
3.2. Clinical and therapeutic findings on Alzheimer’s disease 
 
The present focus for AD treatment includes endogenous molecules that are associated with Aβ 
production and clearance such as the β- and γ-secretases, insulin-degrading enzymes namely, Int. J. Mol. Sci. 2009, 10                 
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neprilysin, and immunotherapeutic-based approaches. Recent evidence from preclinical transgenic 
mice models proposed that deposited Aβ could be removed by modulating particular endogenous 
inflammatory processes. Chang et al. [133]
 revealed that the structure-based design of memapsin 2 (β-
secretase) inhibitors linked to a carrier peptide inhibits the production of Aβ. Researchers used an 
intra-peritoneal formulation of the conjugated inhibitors on transgenic mice with AD and the results 
indicated a major decrease of Aβ levels in the plasma and brain. Acetylcholinesterase inhibitors 
(AChEI) are commonly used in the treatment of AD [134]. The mechanism of action is through 
increasing the concentration of acetylcholine to improve cognitive symptoms. However, the major 
limitation of AChEI is frequent dosing that requires nursing of patients. Ideal therapies could provide 
long-term controlled drug delivery. Donepezil (Aricept
®), a tablet preparation, is administered once 
daily. Rivastigmine (Exelon
®), available as a capsule or as a liquid is administered once or twice daily 
depending on the therapeutic goal [135]. Galantamine is also currently used for the treatment of AD. 
Results from clinical trials have suggested that galantamine may improve the cognitive performance in 
individuals with AD [136]. Research has shown that deterioration of cells that produce acetylcholine in 
the brain affects thought processes. Galantamine is thought to work in two ways by inhibiting AChEI 
and may also stimulate nicotinic receptors in the brain to release additional acetylcholine [136]. 
Reminyl
® is available as an oral tablet of galantamine that requires twice daily administration [137]. A 
study conducted earlier by Schneider, [138] revealed that galantamine consistently failed to show 
statistically significant treatment effects at doses of 8mg/day and produced adverse gastrointestinal 
symptoms similar to other AChEI with increased dosages.  
Memantine is also used for the management of AD, particularly for senile dementia [139]. The 
majority of current drugs that treat AD, such as galantamine, inhibits acetylcholinesterase that is 
responsible for the metabolism of the brain neurotransmitter, acetylcholine. However, memantine 
functions differently in that it inhibits N-Methyl-D-Aspartate (NMDA) receptors that underlie the 
degeneration of cholinergic cells (1) that are essential for healthy brain function. Over stimulation of 
NMDA receptors is referred to as excite-toxicity which is a common pathway for most neurological 
disorders [139,140].  
Recent attempts were to target M1-muscarinic receptors intended for cognitive enhancement with 
the efficient lowering of Aβ. However, the non-selective nature of these compounds in targeting M1-
receptors resulted in dose-limiting side-effects, precluded further development. Bale, [86] reported that 
muscarinic receptor modulation is a potential therapeutically viable approach and should be further 
explored. Rosenberg, [141] explored the area of gene vaccination to prejudice the immune response to 
Aβ. The gene-gun-administered genetic immunization with the Aβ(42) gene proved to be effective in 
eliciting humoral immune responses without a significant T-cell-mediated immune response to the Aβ 
peptide. This immunotherapeutic approach could be a breakthrough in the immunotherapy of AD 
[141]. The recent progress in defining the genotype-phenotype relationships in familial AD is a 
growing consensus that the most effective treatments for AD may be those that interrupt an obligatory 
early step that occurs before a progressive cascade of cell-damaging events. A summary of 
neuroactives that are currently being tested is listed in Table 1. Int. J. Mol. Sci. 2009, 10                 
 
 
2522
Table 1. Neuroactive classes that are currently being investigated for the treatment of 
Alzheimer’s disease. 
Class of Drug  Therapeutic/Pharmacological Activity 
Protease inhibitors  Decrease activity of β- and γ-secretase that cleave 
Aβ from APP  
Extracellular Aβ-binding compounds 
e.g. Cu
2+, Zn
2+ chelators  
Prevent aggregation of Aβ into cytotoxic amyloid 
fibrils 
Immunotherapeutic agents  Induces local and T-cell innate immune response. 
Non-steroidal anti-inflammatory drugs, 
e.g. naproxen, celecoxib, aspirin 
Dampens the innate immune-response thereby 
delaying the progression of AD 
Neuroprotective agents e.g. 
antioxidants, MAO-inhibitors, Ca-
channel blockers and anti-apoptotics 
Interferes with the mechanisms of Aβ-triggered 
putative neurotoxicity 
Statins, e.g. simvastatin  Decreases cholesterol which is a major risk factor in 
amyloid accumulation thereby lowering the risk of 
AD 
Hormonal replacement, e.g. estrogens  Decreases the risk of developing AD in 
postmenopausal woman.  
Cholinergic replacement agents and 
cholinesterase inhibitors, e.g. tacrine, 
donepezil, galantamine 
Symptomatic treatment of AD 
Trophic factors   Prevent degeneration of axotomized cholinergic 
septal and BF neurons by regulating hippocampal 
NGF, APP and ACh-mediated activity  
Environmental enrichment agents  Lead to pronounced reductions in cerebral amyloid 
deposits thereby lowering the risk of AD 
 
In AD senile plaques of Aβ are deposited and neuro-inflammation due to innate immune responses 
against Aβ is thought to cause degeneration of synapses and neural processes [142]. Earlier studies 
discovered that immunization of amyloid precursor protein (APP) in transgenic mice with Aβ reduced 
senile plaques and prevented new deposits of Aβ [143]. It was also found that antibodies to Aβ had a 
similar effect. Since immunized mice showed improvement of cognitive functions, an active 
immunization method was tested in humans. However, the trial was halted due to sub-acute meningo-
encephalitis as a result of T-cell mediated autoimmune responses evolved as a side-effect [142]. A safe 
oral Aβ vaccine using adeno-associated virus vector has been developed which has shown to elevate 
antibodies and maintaining high titres over 6 months. APP transgenic mice and old monkeys have 
shown significant reduction of amyloid burden without any side-effects. Since Th1 immune responses 
were suppressed in the gut immune system, it is thought that immunization is a promising way to treat 
and prevent AD [142-144]. Int. J. Mol. Sci. 2009, 10                 
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4. Overview of Parkinson’s Disease  
 
James Parkinson firstly reported Parkinson’s disease (PD), in 1817 (Hoxton, London) as “the 
shaking palsy”. This is the second most common neurodegenerative disorder after AD. The etiology of 
PD is still being researched with few speculations as to the cause of the sporadic idiopathic 
Parkinson’s syndrome. The world prevalence of PD is approximately 150 individuals per 100 000 and 
increasing rapidly in those over 70 years of age [145]. Risk factors include demographics such as age, 
sex, race and geographical location. For instance, there is a greater frequency of PD in Europe than in 
North America. Older Caucasian males in industrialized regions are at a greater risk of developing PD 
than those in less industrialized regions. Exposure to diminutive doses of methylphenyl-
tetrahydropyridine (MPTP), and previous exposure to viral encephalitis lethargica also present a great 
risk. There is startling evidence that PD is less prevalent in tobacco smokers than in lifelong abstainers 
[145]. Thus far, research has concentrated on genetics, environmental toxins, endogenous toxins and 
viral infection. The key features of PD are tremor, muscular rigidity, bradykinesia, postural instability 
and micrographia [145]. Atypical and typical parkinsonian syndromes are categorized according to the 
neuronal damage caused and the resultant clinical symptoms as described in Table 2. 
Table 2. Clinical symptoms of atypical and typical Parkinsonianism. 
Features  Atypical Parkinsonianism  Typical Parkinsonianism 
Pathological hallmark   Loss of substantia nigra cells and neuronal 
cell degeneration containing DA receptors 
in parts of the CNS such as striatum as 
well as Dementia with Lewy bodies (DLB) 
cortico-basal ganglionic degeneration 
(CBD) 
Loss of substantia nigra cells, 
preserved cells in striatum (basal 
ganglia) and response to DA 
stimulation.  
Clinical symptoms  
 
Resting tremor, slowed movement, muscle 
rigidity, postural instability as well as 
vertical gaze palsy, early postural 
instability (progressive supranuclear palsy) 
and multiple system atrophy (anterocollis). 
Resting tremor, slowed 
movement, muscular rigidity, 
postural instability. 
 
Heredity and family 
history  
More sporadic than familial.   Sporadic and familial. Family 
history plays a major role. 
Genetic involvement  
 
Tau
 positive NFTs present as neuronal 
inclusions, no Lewy bodies.
  
Lewy bodies, mutation of α-
synuclein, parkin and ubiquitin 
genes. 
Aetiology   Sporadic, toxins, MPTP, viruses.   Mostly genetic, mitochondrial 
damage, cell protein disposal. 
Inflammation 
 
Inflammation of substantia nigra and basal 
ganglia. 
Inflammation of the basal 
ganglia.  
 
4.1. The neuropathology of Parkinson’s disease 
 
The neuropathological hallmark of PD is the progressive degeneration of dopaminergic neurons in 
the substantia nigra pars compacta of the brain in addition to astrocytic gliosis and the presence of Int. J. Mol. Sci. 2009, 10                 
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numerous other neuronal systems, associated with widespread occurrence of intracytoplasmic α-
synuclein positive inclusions known as Lewy bodies (LBs) and Lewy neurites of neuronal cells [146]. 
The ubiquitous protein α-synuclein is also involved in the pathogenesis of PD and comprises protein 
filaments of ubiquitin and α-synuclein that are the primary constituent of LBs. Aggregated α-synuclein 
binds the proteasome and potently inhibits proteasomal activity [147,148]. Schultz, et al. [149] 
demonstrated a correlation between α-synuclein and dopaminergic neurotransmission. The genetic 
involvement in PD is still a controversial topic. Mutation of the three genes, namely α-synuclein, a 
pre-synaptic terminal CNS lipophilic protein comprised of 140-amino acids, parkin and ubiquitin C-
terminal hyrolase L1 have been identified as the potential cause of familial PD. However, the major 
constituent of LBs is said to be α-synuclein [150]. Mutation of α-synuclein on chromosome 2p13 and 
ubiquitin carboxyl-terminal hydroxylase L1 (UCHL1) on chromosomes 4p14-16.3, account for 
familial forms of PD particularly the autosomal dominant type [151,152]. Although only few families 
have thus far been identified with mutation of these genes, tau has been identified as a causative gene 
for frontotemporal dementia and Parkinsonism [153]. The onset of PD is typically during the fifth or 
sixth decade of life. However cases from as early as 20-40 years have been observed, where the 
disease is termed juvenile Parkinsonism.  
In addition, studies showed the onset of lesions in the dorsal motor vagals nucleus and related 
medullary nuclei, constituting the "gain setting system" of the lower brainstem, and the olfactory 
system with ascending progression to the ceruleus complex, magnocellular nuclei of the basal 
forebrain system, substantia nigra compacta (SNc)  and subnuclei of thalamus amygdala, and the 
allocortex, with inconsistent involvement of the isocortex [154,155]. The initial lesions in the lower 
brainstem and olfactory system may explain initial autonomic and olfactory impairment that may 
precede the somato-motor dysfunctions. The pattern of fully developed lesions may explain the 
complex somatomotor, autonomic, and behavioral symptoms. The major clinical subtypes of PD 
showed specific lesion patterns with neuropathophysiological and therapeutic relevance [155]. 
Akinesia-rigidity was significantly correlated with SNc neuron loss (ventrolateral part) and dopamine 
loss in the posterior striatum. The onset of clinical motor symptoms occurred with approximately 50% 
of SNc neuron loss and a reduction of striatal dopamine uptake and dopamine transporter loss by 56 – 
80% [156,157]. Reduced dopaminergic input to the putamen caused an increased activity of the 
GABAergic indirect striatal efferent loop via SNr and medial globus pallidus (Gpi) leading to 
increased inhibition of the thalamocortical motor loop with reduced cortical activation [156]. 
Disinhibition of the indirect pathway leads to hypoactivity of external globus pallidus (Gpe) and 
subthalamic nucleus (STN) while increased excitatory drive from hyperactive STN may sustain 
progression of neurodegeneration in PD [158]. Increased GAGAergic activity reduced by L-dopa 
treatment disappeared in the course of disease and may induce changes in NMDA receptors and 
glutamatergic synapses, favoring motor complications [159]. The uncoupling of receptor systems is a 
major cause of drug resistance and adverse L-dopa effects [160]. The tremor-dominant type showed 
less severe neuronal loss in the lateral SNc, and additional damage to the retrorubral A-8 field 
projecting to the matrix of dorsolateral striatum and ventromedial thalamus [161], influencing the 
striatal efflux via SNr and the thalamus to prefrontal cortex [162]. PETand fMRI studies suggested 
increased activity of the ventral thalamic projections (VIM) and of cerebellar connections [163] having 
considerable implications for stereotactic treatment of PD. Int. J. Mol. Sci. 2009, 10                 
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Further recent elucidation of the molecular mechanisms implicated in PD has been demonstrated by 
Winderickx et al. [164]. The study has indicated that the yeast Saccharomyces cerevisiae is a suitable 
model to decipher molecular mechanisms involved in a variety of NDs caused by aberrant protein 
folding such as in PD. Among the 6 genes distinctly linked to familial PD, mutations in α-synuclein 
and LRRK2/dardarin resulted in autosomal dominant forms of PD, while mutations in parkin, DJ-1, 
PINK1 and ATP13A2 are implicated in autosomal recessive forms of PD. The association of other 
genes, such as the ubiquitin carboxy-terminal esterase L1, UCH-L1, the mitochondrial serine protease 
Omi/HtrA2 or the synaptic protein Synphilin-1, was less apparent. In Figure 3, Winderickx et al., 
[164] depicted the major pathways involved in α-synuclein-mediated cell death, namely α-synuclein 
aggregation, obstruction of vesicular traffic and protein degradation, and mitochondrial dysfunction. In 
both neurons and yeast cells, aggregation of α-synuclein occurring simultaneously with reactive 
oxygen species (ROS) formation in vitro, was reported to hamper vesicle dependent processes, such as 
endocytosis and endoplasmic reticulum-to-Golgi traffic, to induce the unfolded protein response 
(UPR) and to block the ubiquitin–proteasome system (UPS). Sustained induction of the UPR and 
impairment of the UPS are purported to trigger the production of ROS. Furthermore, α-synuclein 
protofibrils cause vesicle permeabilization leading to disrupted homeostasis of dopamine (DA) 
metabolism, increased cytoplasmic DA levels, and enhanced oxidative stress in dopaminergic neurons. 
The production of ROS as described has adverse effects on mitochondrial function, and conversely, the 
oxidative stress induced by mitochondrial dysfunction is known to affect the UPS. In addition, a direct 
physical interaction of α-synuclein with the outer membrane of mitochondria was demonstrated and 
proposed as an alternative link explaining mitochondrial dysfunction in dopaminergic neurons. Finally, 
increased oxidative stress enhances the aggregation of α-synuclein. Figure 2 also depicts the various 
PD-associated proteins and their homologous counterparts in yeast, i.e. DJ-1 and its homologue Hsp31 
as well as HtrA2 and its orthologue Nma111. Although Winderickx et al., [164] reported the 
involvement of HtrA2 and DJ-1 in PD through yeast studies, the results were unable to confirm the 
role of Nma111 in α-synuclein-mediated apoptotic cell death and a protective function of Hsp31 have 
not yet been demonstrated. The role of LRRK2 in neuronal loss in PD is not yet known. 
Furthermore, there is striking evidence on the anomalous accumulation of iron in the brain of PD 
patients, with the highest concentration in the substantia nigra, globus pallidus, red nucleus, caudate 
nucleus, putamen, substantia nigra pars compacta, microglia, as well as in association with 
neuromelanin. The level of iron within the brain increases with age, and the increased iron levels have 
been observed in several NDs. Neuroscientists have acknowledged the degenerative effects of free iron 
on neurons in the brain and its relation to the progression of PD [165,166]. Redox-active iron 
constitutes part of LBs. Iron and free radical generators such as DA and hydrogen peroxide are thought 
to augment the generation of toxic ROS and the aggregation of inert α-synuclein to toxic aggregates 
[167]. Insight on a few biochemical experiments have exposed the complexation between nicotine and 
free iron during the electrochemical actions of the Fe
2+/Fe
3+ redox couple [168].  
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Figure 3. Molecular mechanisms leading to cell death in neurons and the yeast PD model 
(Adapted from: Winderickx et al. [164]). 
 
 
It is well known that α-synuclein is broadly expressed in the
  brain, where it interacts with 
membranes, vesicular structures,
 and a variety of other proteins. In mammalian cells α-synuclein has 
been reported
 in the nucleus, cytosol, associated with membranes and, in diseased
 brains, in large 
cytoplasmic inclusions LBs [169]. Synucleinopathies
 are classified as protein-misfolding disorders 
[169]. Given
  the strong conservation of protein folding, membrane trafficking,
  and protein QC 
mechanisms between yeast and higher eukaryotes,
 Outeiro and Lindquist, [169], used Saccharomyces 
cerevisiae to uncover and establish basic
 aspects of both normal and abnormal α-synuclein biology.
 In 
order to explore α-synuclein dynamics in living cells, they created an α-synuclein-GFP
  (green 
fluorescent protein) fusion that was not subject to proteolysis
 in yeast cells as related fusions have been 
in
  mammalian cells [170]. By integrating the construct into the genome
  under the control of a 
galactose-inducible promoter allowed
 routine manipulations in the absence of α-synuclein expression. 
Upon
 induction with galactose, wild-type (WT) α-synuclein-GFP localized at the plasma membrane 
and a smaller quantity accumulated in the
 cytoplasm. Compared with other GFP fusion proteins,
 α-
synuclein did not localize in mitochondrial or nuclear membranes.
 Thus, reminiscent of its selectivity 
for membranes with particular
 lipid compositions in vitro, α-synuclein had a high intrinsic selectivity
 
for particular cellular membranes in vivo.
 Results from this study in conjunction with others have 
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revealed that the approach is flexible and may provide an opportunity to analyze
  the molecular 
pathways underlying normal α-synuclein biology
  and the neuropathogenic consequences of its 
misfolding [170,171]. 
 
4.2. Clinical and therapeutic findings on Parkinson’s disease 
 
The neurochemical effect is a decline in DA concentrations in the basal ganglia. The clinical signs 
of PD include mass loss and gastrointestinal symptoms such as indigestion and constipation due to the 
α-synuclein pathology in the autonomic nerves and ganglia. At present, the diagnosis of PD depends 
on recognizing clinical patterns as there are no viable laboratory-based diagnostic tests. Positron 
Emission Tomography (PET) is only used in research and conventional imaging is unhelpful [172]. 
Medical science lacks an accurate blood or imaging diagnostic test for PD, though tests can exclude 
other conditions. Diagnosis is based on an evaluation of symptoms best accomplished by PD medical 
specialists. The progression of PD varies and therefore treatment is individualized and focuses on 
relieving disabilities while minimizing side-effects caused by the drugs administered. While there is no 
cure, therapies can minimize symptoms and maximize the function and quality of life of those afflicted 
with PD. Even though PD is incurable and drugs are unable to alter the cause of the disease, levodopa 
(L-dopa) and other DA agonists are used in an attempt to restore DA activity. DA does not cross the 
BBB and has no therapeutic effect if administered systemically. However, L-dopa, the gold standard 
treatment for PD and an immediate precursor of DA, penetrates the BBB where it is decarboxylated to 
DA [173, 174]. L-dopa is usually combined with a decarboxylase inhibitor, carbidopa or benserazide, 
to reduce the peripheral conversion of L-dopa to DA thus reducing the peripheral side-effects. L-dopa 
remains the most effective treatment for the slowness of movement, increased muscle tone and tremor 
that are typical of PD [175]. 
Conversely, the inhibition of decarboxylase is associated with O-methylation of L-dopa leading to 
poor therapeutic responses. This further requires a catechol-o-methyltransferase inhibitor (COMT) 
such as entacapone to inhibit the reaction and reduce the end-of-dose fluctuations of L-dopa. Other 
directly acting DA receptor agonists include drugs such as bromocriptine, lisuride, pergolide, 
cabergoline, pramipexole and ropinirole acting principally on D1 receptors located in the zona 
compacta of the substantia nigra, D2 receptors found on striatal neurons, and D3-5 receptors [176]. 
These drugs are used as an alternative or an addition to L-dopa therapy. Apomorphine, a potent D1 and 
D2 agonist is administered subcutaneously by metered-dose infusion to level the fluctuations in 
response to L-dopa. Woitalla et al. [177] demonstrated the safety, tolerability and effectiveness of a 
transdermal formulation of lisuride that offers a promising therapeutic modality to manage the 
frequency and intensity of the motor fluctuations of PD. Other approaches of treatment include the use 
of selective monoamine oxidase-B (MAO-B) inhibitors such as rasagiline, a drug demonstrating 
neuroprotective properties that are independent of its MAO inhibitory activity [178]. 
Supplementary agents that are also used include antioxidants such as vitamins C and E that act as 
neuroprotectants [179]. Tissue transplantation of fetal or autologous DA containing adrenal medulla 
and glial cell-line neurotrophic releasing factor (GDNF) into the cerebral ventricles or basal ganglia 
failed to show any major clinical improvement. A group of scientists have recently applied the 
technique of introducing copies of genes into the brain to enhance the production of neurotransmitters Int. J. Mol. Sci. 2009, 10                 
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such as DA. Candidate genes included tyrosine hydroxylase and GTP cyclohydroxylase I. Genes for 
neurotophic factors or anti-apoptotic agents can be used as a neuroprotective approach [180]. Thus, 
this research showed promise for the treatment and possible cure of PD. However the safety and 
efficacy of this approach requires further comprehensive tests to be conducted. 
Clinical studies on cell transplantation as an alternative therapy for PD have been conducted since 
the early 1980s. Stem cells are used as a therapeutic alternative for PD. The current leading scientific 
explanation is that stem cells may surrogate the damaged cell population (Figure 4). In an attempt to 
increase the generation of DA in the brain, non-neuronal cells were transplanted, both without genetic 
manipulation and with genes like tyrosine hydroxylase, in animal models with PD [181]. The 
limitation of this study was due to the cells’ non-neuronal origin, leading to uncontrolled development 
of these cells. Transplanted neuronal cells are likely to survive and grow into neurons with functional 
synapses and lead to meaningful clinical improvement. Fetal dopaminergic cells originating in the 
ventral mesencephalic tissue were acquired for such experiments. Transplanted cells are anticipated to 
be only functional if they have the same capacity as the original neurons, such as synthesizing, 
releasing and metabolizing neurochemicals. The discovery of this self-renewing phenomenon of 
embryonic and adult stem cells to produce differentiated tissues confers a promising future for tissue-
replacement in NDs. 
Figure 4. Depiction of adult neural stem demonstrating their intrinsic potential to generate 
cell types of the brain and spinal cord (Adapted from: Karimi and Eftekharpour, Fehlings 
lab, McEwan Centre for Regnerative Medicine; 
www.mcewencentre.com/res_prog_scnd.asp, [182]). 
Adult Brain
Brain-derived neural stem cells (NSCs)
 
 
O'Brien et al. [183] conducted a study to examine the extent and pattern of DA
 transporter loss 
using iodine I 123-radiolabeled 2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl)
  nortropane 
(FP-CIT) with Single-Photon Emission Computed Tomography
 (SPECT) in DLBs compared with 
other dementias and to assess
 its potential to enhance a differential diagnosis. They established that 
significant reductions (p < 0.001) in FP-CIT binding
 occurred in the caudate and anterior and posterior 
putamens
 in subjects with DLB compared with subjects with AD and controls.
 Transporter loss in Int. J. Mol. Sci. 2009, 10                 
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DLBs was of similar magnitude to that seen
 in PD, but with a flatter rostrocaudal (caudate-putamen) 
gradient
 (p = 0.001), while the greatest loss in all three areas was observed
 in those who had PD and 
dementia. Both region of interest analysis
 and visual ratings provided superior separation between 
DLBs and
 AD (region of interest: sensitivity, 78%; specificity, 94%;
 positive predictive value, 90%) 
but not among subjects with
 DLB, PD, and PD with dementia. It has thus been concluded that DA 
transporter loss can be detected
 in vivo using FP-CIT SPECT in DLB [183,184].  
 
4.3. The symptomatic treatment of Parkinson’s disease 
 
In PD, cells are destroyed in the substantia nigra of the brain stem that transmits fibers to the corpus 
stratia which has DA-releasing cells. A challenge is that when symptoms develop, patients have 
already lost 80-90% of DA-producing cells [185]. Since certain drugs and other conditions can cause 
Parkinson's-like neurologic symptoms, the misdiagnosis of PD is frequent [185]. Besides L-dopa, the 
non-ergoline D2-agonists, ropinirole, is also used for the symptomatic treatment of PD [186]. The 
efficacy of ropinirole was investigated in placebo-controlled studies by Brooks et al., [187]. One study 
used ropinirole as monotherapy in early PD while others employed it as an adjunct to L-dopa in 
patients who experienced fluctuations in motor response. Ropinirole therapy over 12 weeks was found 
to be effective for symptomatic therapy in both patient groups. Unlike other DA agonists, CNS side-
effects were of the same magnitude as for patients receiving a placebo [187]. The antiviral agent, 
amantadine, is also used for the symptomatic
 treatment of PD for over 30 years [188,189]. Studies 
have suggested that amantadine may have a neuroprotective effect
 in PD mediated through
 N-methyl-
D-aspartate (NMDA) receptor antagonism, DA-uptake
  blockade or other mechanisms [188,189]. 
Selegiline, a monoamine oxidase-B (MAO-B) inhibitor has also been used for the symptomatic 
treatment of PD. Selegiline selectively and irreversibly inhibits intracellular and extracellular MAO-B 
and therefore reduces or delays the degradation of DA while also inhibiting the reuptake of DA from 
the synaptic cleft [190]. Furthermore, it has been observed that the addition of selegeline
 to L-dopa 
may allow a reduction of the L-dopa dose [191,192]. However, selegiline may also potentiate the side-
effects of L-dopa such as dyskinesias and psychiatric tendencies [193].  
The anticholinergic drugs such as biperiden, procyclidine, orphenadrine, benzhexol, and 
benztropine are used to improve the tremor and stiffness to a greater degree than akinesia
 and are 
overall mildly effective [194]. Due to a peripheral parasympathomimetic
 action, side-effects such as 
glaucoma, dryness of the mouth, blurred
 vision, urinary retention, and constipation may occur. Since 
anticholinergics
  have a relatively high potential for causing or worsening confusional
  states and 
impairing concentration, they are used cautiously in the
 elderly [195]. The addition of a COMT 
inhibitor as adjunctive therapy
 to L-dopa with either carbidopa or benserazide reduces the peripheral
 
metabolism of L-dopa. This prolongs the plasma half-life of L-dopa
  and increases the quantity 
available in the brain [196,197]. COMT inhibitors are however associated with side-effects such as 
potentiation of dyskinesias, nausea, diarrhea, discoloration of the urine and sleep
 disturbances.  
In addition, results of the first placebo-controlled, multicenter clinical trial of the compound 
Coenzyme Q10 (CoQ10) undertaken by Shults and coworkers [198], suggested that CoQ10 may slow 
disease progression in patients with early-stage PD. The phase II study enrolled 80 subjects with early 
PD who did not require treatment for their disability to determine if CoQ10 is safe and if it has the Int. J. Mol. Sci. 2009, 10                 
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capacity to reduce the rate of functional decline in PD. The subjects underwent evaluation with the 
Unified Parkinson Disease Rating Scale (UPDRS) at the screening, baseline, and were followed up for 
16 months or until disability requiring treatment with L-dopa had developed. The primary response 
variable was the change in the total score on the UPDRS from baseline to the last visit. Results have 
shown that CoQ10 was safe and well tolerated at dosages of up to 1200mg/d. Less disability developed 
in subjects assigned to CoQ10 than in those assigned to the placebo, and the benefit was greatest in 
subjects receiving the highest dosage. CoQ10 appeared to slow the progressive deterioration of function 
in PD. However the results need to be confirmed in a larger group of subjects [198]. 
Embryonic/fetal cell transplantation has been introduced, as a treatment option for PD, based on the 
hypothesis that embryonic or fetal neuronal cells would regenerate the damaged neuronal tissue in 
patients with PD, thereby reducing their symptoms and/or slowing disease progression. Dopaminergic 
neuronal cells are obtained from the brainstem of aborted embryos/fetuses aged 6-15 weeks post-
conception. The cells are transplanted into the brain of a patient with PD. Other sources of dopamine 
neuronal cells currently under clinical investigation include (embryonic, fetal, and adult) stem cells, 
adrenal medullary tissue, retinal pigment epithelium, carotid body cells, and autologous and 
xenogeneic neuronal tissue. The majority of studies evaluated involve human fetal mesencephalic 
tissue. The primary outcome measure in all studies was changes in PD motor function. Symptom 
severity was generally assessed with the Unified Parkinson's Disease Rating Scale (UPDRS), assessed 
in the "on-drug" and/or "off-drug" state following an overnight withdrawal of anti-PD medication 
[199,200,201]. In a prospective 24-month double-blind controlled trial by Olanow and coworkers 
[202], patients with advanced Parkinson's disease were randomized into one of three groups [202]. One 
group received bilateral transplantation with one donor per side, one group received bilateral 
transplantation with four donors per side and the last group received a placebo procedure. Changes in 
UPDRS scores from baseline to 24 months post-surgery, assessed in the "on-drug" and "off-drug" 
state, served as the primary outcome measures; secondary outcome measures included dopamine 
production in the patients' brains and motor function as recorded in a patient self-maintained diary. 
There was no significant overall treatment effect. Patients in the placebo and one-donor groups showed 
deterioration whereas those in the four donor group showed some improvement. Fifty-six percent of 
the transplanted patients developed dyskinesia that persisted after overnight withdrawal of 
dopaminergic medication. Therefore the authors concluded that fetal nigral transplantation cannot 
currently be recommended as a therapy for Parkinson's based upon these results [202]. 
 
5. Overview of Amyotrophic Lateral Sclerosis 
 
Amyotrophic lateral sclerosis (ALS) is a progressive degenerative motor neuron disease 
characterized by weakness in limb and bulbar muscles with atrophy, spasticity, weight loss and 
ultimately respiratory failure. The prevalence of ALS is approximately two per 100,000 per annum, 
and it is estimated that there are about 25,000 prevalent patients in North America [203]. The onset of 
ALS may be subtle that the symptoms are frequently overlooked and usually occur between the fourth 
and sixth decade of life. However, any age group from all races and ethnic backgrounds can be 
affected. Men are at a higher risk than women. Also known as Lou Gehrig's disease, ALS is an age-
dependent rapidly progressive disorder of motor neurons with both sporadic and familial forms that is Int. J. Mol. Sci. 2009, 10                 
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ultimately fatal. The disease is virtually always fatal and approximately 50% of patients die within 3-4 
years after the onset of symptomatic weakness. There is a combination of upper motor neuron and 
lower motor neuron abnormalities, and relentless and nearly linear progression of impaired function in 
almost all patients. Approximately 95% of ALS is classic sporadic [204-210]. Sporadic ALS has been 
associated with ‘susceptibility’ genes as the neurodegenerative effect of these genetic changes 
probably depends on interactions with other prevalent, low penetrant genetic defects and/or with 
environmental risk factors. Familial forms with Mendelian inherited ALS are observed in 
approximately 5 – 10% of patients and are clinically and neuropathologically indistinguishable from 
sporadic ALS [204-207]. Motor neurons located in the brain, brainstem, and spinal cord serve as 
controlling units and communication links between the nervous system and the voluntary muscles of 
the body. In ALS, both the upper and lower motor neurons degenerate and neural communications 
with the muscles are impeded. ALS results in progressive muscle weakness, atrophy, fasciculations 
and cramps. The respiratory muscles in the diaphragm and chest wall are also affected, and patients 
lose the ability to breathe without ventilatory support. Patients also face an increased risk of 
pneumonia during later stages of ALS. Death after 3-5 years is mostly from respiratory failure. 
However, approximately 10% of ALS patients survive for 10 or more years [211]. 
 
5.1. The neuropathology of Amyotrophic Lateral Sclerosis: The role of inflammation 
 
The neuro-inflammatory genes implicated in ALS include TNF-alpha, IL- RA, CD86, CD200R and 
Groalpha [212]. The inflammation neuropathology is complemented by glutamate neurotoxicity, 
oxidative stress, aberrant metal ion regulation, apoptosis, as well as abnormal microglial function on 
G93A SOD1 that results in neurodegeneration [213]. Figure 5 depicts SOD-1 mutations that may 
activate caspase-1 and caspase-3, thus potentially increasing free-radical generation, leading to motor 
neuron apoptosis. The activation of caspase-1 leads to interleukin-1 production, which can induce a 
local microglial inflammatory response and increase the number of neurons affected [16]. 
Figure 5. Schematic of SOD-1 mutations activating cell death pathways in familial 
Amyotrophic Lateral Sclerosis (Source: Yuan and Yankner, [16]). 
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5.2. Clinical and therapeutic findings on Amyotrophic Lateral Sclerosis 
 
No single test can provide a definitive diagnosis of ALS, although the presence of upper and lower 
motor neuron signs in a single limb is strongly suggestive. Diagnosis of ALS includes signs and 
symptoms of both upper and lower motor neuron damage that cannot be attributed to other causes. The 
clinical representation is a progressive spastic tetraparesis or paraparesis including fasciculations, 
cramping, stiffness of muscles, muscle weakness, slurred and nasal speech, and difficulty chewing or 
swallowing progressing to atrophy. The early symptoms depend on the region that is damaged first. 
Atrophy eventually spreads to other regions of the body as the disease progresses and leads to mass 
loss, dysphagia, dysarthria, muscle spasticity, and hyper-reflexia with an overactive gag reflex. The 
Babinski's sign is also an indicator of upper motor neuron damage. Diagnostic tests include 
electromyography (EMG), for electrical activity in muscles. EMG findings may complement the 
diagnosis of ALS. Another common test measures nerve conduction velocity (NCV) for peripheral 
neuropathy or myopathy as a differential diagnosis for ALS. A magnetic resonance imaging (MRI) 
scan may be used for assessing the brain and spinal cord. A few researchers have investigated the role 
of glutamate, a brain neurotransmitter, in motor neuron degeneration. It has been established that ALS 
patients have elevated levels of glutamate in serum and spinal fluid [214-217]. In vitro studies   
have demonstrated that neurons begin to degrade when exposed for long periods to excessive 
quantities of glutamate.  
However the mechanism of glutamate build-up is still to be determined. Furthermore, autoimmune 
responses have also been implicated in motor neuron degeneration in ALS [218]. The cures for ALS is 
not known and successful pharmacotherapy intended to slow, seize or repeal the disease progression, 
remains a challenge [212]. However, the US FDA has approved riluzole (Rilutek
®) as a drug for 
treating ALS [219]. Riluzole is able to reduce the damage to motor neurons by decreasing the release 
of glutamate. Clinical trials with ALS patients showed that riluzole does not reverse the damage, but 
prolongs survival by several months, mainly in those with difficulty swallowing and prolongs the time 
before ventilatory support is needed. Supportive care from a multidisciplinary team of health care 
professionals such as general practitioners, pharmacists, physiotherapists, occupational therapists, 
speech therapists, dieticians, social workers, as well as home care and hospice nurses is vital. Drugs to 
help reduce fatigue, ease muscle cramps, control spasticity, and reduce excess saliva and phlegm may 
be administered. Pharmacists may provide advice on the proper use of medications and monitor a 
patient's prescription to avoid risks of drug interactions. Potential therapies for ALS being investigated 
include antioxidants and neurotrophic factors to prevent neurodegeneration. Recent advances in 
research have also identified an ubiquinated protein that is commonly found in the majority of ALS 
cases. In healthy nerve cells the protein, TDP-43, is typically localized in the nucleus. However, in 
affected nerve cells, TDP-43 is only found in the cytoplasm. The cytoplasm is located outside of the 
nucleus and is the primary site for chemical activity in the cell. The accumulation of abnormal TDP-43 
in this area of the cell is speculated to cause a loss in cellular function (due to the absence of normal 
TDP-43 in the nucleus), thereby impairing the viability of the affected nerve cells [220,221]. 
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5.3. The symptomatic treatment of Amyotrophic Lateral Sclerosis  
 
Since patients with ALS have symptoms of progressive muscle weakness, disturbed speech and 
swallowing, and in the terminal phase respiratory weakness, treatment options may be introduced 
when the patient is emotionally capable and prior to dysarthria [222]. Cramps, pathological crying or 
laughter, spasms, and spasticity are treated symptomatically. Sialorrhoea which results from ALS is 
caused by difficulty in swallowing and is normally accompanied by a danger in aspiration. It can be 
halted by the use of medication, radiotherapy or by injecting botulin toxin into the salivary glands. 
Dysphagia results in mass loss which can be prevented by eating frequent small meals or if necessary 
performing a percutaneous endoscopic or radiological gastroscopy. The terminal phase of ALS is 
associated with restlessness, anxiety, pain and dyspnoea and it requires a careful and well co-operated 
multidisciplinary palliative care [222]. Minimal research progress has been made in terms of 
developing new strategies for the symptomatic management of ALS. 
The neuroactive drug, riluzole that reduces glutamate release from nerve terminals has been 
approved for treatment of patients with ALS in most countries. However, questions persist regarding 
the clinical utility of riluzole due to its high cost and modest efficacy. Miller and coworkers [223], 
reviewed the efficacy of riluzole in prolonging survival, and in delaying the use of surrogates 
(tracheostomy and mechanical ventilation) to sustain survival in patients with ALS. In their study 
100mg of riluzole was administered daily and was found to be reasonably safe and potentially 
prolonged the median survival of ALS patients by approximately 2 – 3 months. In addition evidence 
from 4 randomized clinical trials involving 1477 patients with ALS was also examined and concluded 
that patients taking riluzole probably survive longer than patients taking the placebo. However, the 
beneficial effects were modest and the drug was found to be rather expensive [223]. Further studies are 
required, especially to determine whether patients treated earlier or older, more advanced patients with 
longstanding disease derive the same benefit. In terms of side-effects the most frequent are nausea and 
asthenia and liver function requires monitoring [223]. 
 
6. Overview of Huntington’s Disease 
 
Huntington disease (HD) is a progressive heredo-neurodegenerative disease manifested by chorea 
and other hyperkinetic (dystonia, myoclonus, tics) and hypokinetic (parkinsonism) movement 
disorders. In essence, HD is an autosomal dominant inheritance with complete penetrance, caused by 
mutation associated with trinucleotide repeat expansion repetition at the IT15 gene on the short arm of 
chromosome 4p which encodes a 349 kD huntingtin protein [224]. It is also known as a polyglutamine 
disease [225]. The macroscopic signs of HD are the bilateral marked atrophy of the putamen and the 
head of the caudate nucleus. At late stages of HD there is a tendency of small amino-terminal 
fragments with mutants to self-aggregate with an altered conformation. The onset of HD is usually in 
the third or fourth decade of life, although it can also attack children and the elderly. Worldwide 
prevalence of HD is approximately 5 in 100,000 persons [224].  Int. J. Mol. Sci. 2009, 10                 
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6.1. The neuropathology of Huntington’s disease 
 
A growing number of NDs including HD have been found to belong to the group of CAG triplet 
repeat disorders [226]. These disorders are caused by an elongated CAG repeat located in the coding 
region of the respective genes, which is translated into a polyglutamine tract. The mechanism by which 
CAG repeats elongate is currently unknown and therefore is the subject of intensive investigation. 
Characteristic features of CAG repeat disorders are autosomal dominant inheritance, late onset, 
selective neurodegeneration, genetic anticipation, a pathological threshold at which the mutation 
becomes virulent, and an inverse correlation between CAG repeat length and age at disease onset [227-
230]. Genetic mutation discovered in the chromosome 4 (4p16.3), in conjunction with a variable 
expansion of a trinucleotide CAG-repeat sequence, encoding polyglutamine, in axon 1 in huntingtin 
gene leads to the translation of an extended glutamine sequence in huntingtin, a predominantly 
cytoplasmic protein that is found in neurons throughout the brain [231]. The N-terminal fragments of 
mutant huntingtin subsequently aggregate in neurons causing progressive neuronal dysfunction and 
fatality. Adult HD sufferers have CAG expansions of approximately 40 – 55 repeats, whilst childhood 
cases are associated with up to 70 repeats. The oxidative DNA damage observed in HD can be caused 
directly and/or indirectly through altered mitochondrial function [232]. In the hereditary HD, 
expression of mhtt in HD can directly increase production of ROS and subsequent oxidative DNA 
damage through defects in mitochondria (Figure 6). 
Figure 6. Schematic depicting a pathway of oxidative damage in HD (Source: Trushina 
and McMurray, [232]). 
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The main features of HD are sub-cortical dementia, choreiform movements including tics and 
grimaces, as well as altered moods. The neuropathogenesis begins with the degeneration of the basal 
ganglia and cerebral cortex with fractional loss of striatal neurons. There is marked loss of neurons in 
the caudate nucleus and putamen. Neurochemical transformations include a decline in concentrations 
of cholineacetyl transferase, an enzyme that synthesizes acetylcholine the striatum. There is also an 
increase in transglutaminase, an enzyme that catalyzes aggregates of huntingtin in the cortex, 
cerebellum and corpus striatum.  
The specific progressive atrophy in these brain regions is associated with reactive astrocytosis 
[233]. Within the striatum there is selective loss of medium spiny γ-aminobutyric acid (GABA) Int. J. Mol. Sci. 2009, 10                 
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neurons, which project into the pallidum forming the indirect striatopallidal pathway. Prior to cell 
death, neuronal dysfunction is manifested by abnormalities of dendritic endings. In addition to atrophy 
in the striatum, extensive neuronal cell loss also occurs in the deep layers of the cerebral cortex, white 
matter, hippocampus, amygdala, and thalamus [234]. Studies have shown that the mutation underlying 
HD is an unstable CAG trinucleotide repeat expansion in the first axon of the gene. It ranges from 6-37 
units in healthy individuals, and 38-180 units in HD patients [227,235]. The CAG repeat is translated 
into a polyglutamine stretch, which is conserved in vertebrates, containing 7 glutamines in the mouse 
[229] and only 4 in the puffer fish, [230] but is absent from the Drosophila  protein [236]. The 
predicted huntingtin protein sequence is highly conserved between human, mouse, and puffer fish, but 
showed no significant homology with other proteins in databases. The only functional motives that 
have been discovered are a putative leucine zipper and a HEAT repeat [237]. HEAT repeats consist of 
two hydrophobic α-helices and were found in proteins involved in cellular transport processes. Few 
studies have found huntingtin interacting protein–1 (HIP1) associated with the HEAT repeat [238]. 
However, whether this sequence motive is essential for protein-protein interaction is yet to be 
determined. HIP1 has been identified using the yeast two-hybrid system. The predicted amino acid 
sequence of HIP1 exhibits significant similarity to cytoskeleton proteins, suggesting that HIP1 and the 
huntingtin protein play a functional role in the cell filament networks and/or vesicle trafficking [239], 
which associates with the membrane cytoskeleton and plays a functional role in endocytosis [240]. 
Recently, colocalization of HIP1 and huntingtin with clathrin-coated vesicles in mammalian cells has 
been described, suggesting that both proteins also play a functional role in endocytosis in higher 
eukaryotes [241, 242]. This hypothesis is substantiated by the finding that huntingtin and its associated 
protein, huntingtin-associated protein-1 (HAP1), [243] may be transported along microtubules in 
axons [244]. In addition, direct binding of HAP1 with p150Glued of the dynactin complex, which is 
critical for retrograde movement of vesicles along microtubules, has been described [245]. Overall, 
these findings indicate that a protein complex consisting of the proteins HIP1, HAP1, and huntingtin is 
functionally involved in endocytosis and retrograde transport of clathrin-coated vesicles along 
microtubules. However, additional cell biology and biochemical studies will be necessary to address 
this hypothesis in more detail. The generation of HIP1 and SH3GL3 knockout as well as transgenic 
animal models may help elucidate the normal function of huntingtin and may also help to understand 
the key steps in the neuropathogenesis of HD.Giorgini and coworkers [246], focused on elucidating the 
molecular mechanisms for the development of newer therapeutic strategies for HD using a yeast model 
of mutant huntingtin toxicity. Conserved cellular pathways involved in mutant huntingtin toxicity and 
thus candidate drug targets for the treatment of HD have been identified. HD is caused by expansion of 
a polyglutamine tract in the protein huntingtin, which leads to its aggregation in nuclear and 
cytoplasmic inclusion bodies. Giorgini and coworkers [246] have identified 52 loss-of-function 
mutations in yeast genes that may enhance the toxicity of a mutant huntingtin fragment and have also 
identified 28 gene deletions that suppress toxicity of a mutant huntingtin fragment. The suppressors 
may play a role in vesicle transport, vacuolar degradation, transcription and prion-like aggregation. 
Among the most potent suppressors identified was Bna4 (kynurenine 3-monooxygenase), an enzyme 
in the kynurenine pathway of tryptophan degradation that has been linked directly to the 
neuropathophysiology of HD in humans by a mechanism that may involve reactive oxygen species. 
Their work provides new insights and is suggestive of a conserved mechanism of polyglutamine Int. J. Mol. Sci. 2009, 10                 
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toxicity from yeast to humans and identifies new candidate therapeutic targets for the treatment of  
HD [246].  
Vonsattel and coworkers, [247] explored the neuropathological classification of HD. In postmortem 
brain specimens from 163 clinically diagnosed cases of HD the striatum exhibited marked variation in 
the severity of neuropathological involvement. A system for grading the severity was established by 
Vonsattel and coworkers, [247] by macroscopic and microscopic criteria, resulting in five grades (0-4) 
designated in ascending order of severity. The grade correlated closely with the extent of clinical 
disability as assessed by a rating scale. In five cases of clinically diagnosed HD there were no 
discernible neuropathological abnormalities (grade 0), suggesting that the anatomical changes lag 
behind the development of clinical abnormalities. In eight cases, neuropathological changes could only 
be recognized microscopically (grade 1). The earliest changes were seen in the medial paraventricular 
portions of the caudate nucleus (CN), in the tail of the CN, and in the dorsal part of the putamen. 
Counts of neurons in the CN reveal that 50% were lost in grade 1 and that 95% were lost in grade 4. In 
addition, astrocytes were greatly increased in grades 2 – 4. These studies indicated that analyses of the 
CN in grade 4 may reflect mainly its astrocytic composition with a component of remote neurons 
projecting to the striatum. Due to the relative preservation of the lateral half of the head of the CN in 
grades 1-2, these regions would reflect early cellular and biochemical changes in HD [247]. 
 
6.2. The symptomatic treatment of Huntington’s disease  
 
In HD, a variety of psychiatric and behavioral symptoms, along with cognitive decline, contribute 
significantly to the patient's disability. Since there are no effective neuroprotective therapies that delay 
the progression of HD, symptomatic treatment remains the cornerstone of clinical management [248]. 
Several classes of drugs have been used to ameliorate the various symptoms of HD, including typical 
and atypical neuroleptics, DA antagonists, antidepressants, antiglutamatergic drugs, GABA agonists, 
antiepileptics, acetylcholinesterase inhibitors, and botulinum toxin [248]. Recently, surgical 
approaches including pallidotomy, deep brain stimulation and fetal cell transplants are being used for 
the symptomatic treatment of HD. Importantly is that the selected therapy must be customized to the 
needs of each patient in order to minimize the potential side-effects.  
Although significant advances in identifying and clarifying the molecular and mechanistic pathways 
that lead to the progression of HD have been realized, effective pharmacotherapy remains a mystery 
and no treatment arrests the disease. Olanzapine 2.5 mg daily, a dopaminergic-serotonergic antagonist, 
has been suggested as an alternative therapy for HD [249,250]. Olanzapine 5 mg per day is 
administered with lofepramide 140mg daily for psychiatric improvement. The psychiatric 
manifestations were shown to improve in patients treated with a daily combination of 5 mg olanzapine 
and 1,500mg valproic acid [251]. 
 
7. Other Related Atypical Neurodegenerative Disorders  
 
NDs not extensively reviewed in this paper include disorders such as Wilson’s disease (WD). Also 
known as hepatolenticular degeneration, WD is an autosomal recessive inherited disease that causes 
excessive copper accumulation in the liver or brain. Spontaneous mutation of the ATP7B gene located Int. J. Mol. Sci. 2009, 10                 
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on chromosome 13, results in anomalous copper metabolism causing psychiatric and extrapyramidal 
symptoms [252]. Pick’s Disease (PkD) is characterized by the tau-positive Pick’s bodies. The 
symptoms of PkD are usually mistaken for AD and usually discovered during postmortems [253,254]. 
Multiple sclerosis (MS) that may be caused by genetic polymorphism (although controversial), results 
in CNS symptoms such as slurred speech, blurred vision and urinary incontinence [255,256]. Axonal 
loss is a major pathologic process responsible for irreversible neurologic disability in patients with 
multiple sclerosis (MS). Pathologic studies implicate inflammatory demyelination as a principal cause 
of axonal transection and subsequent axonal degeneration. Axonal degeneration caused by chronic 
demyelination in the absence of active inflammation may also contribute to progressive disability in 
the later stages of the disease. Studies using magnetic resonance spectroscopy suggest that axonal loss 
begins at the onset of the disease, and studies using MRI have documented brain atrophy in the earliest 
stages of MS [257]. Although these conditions are less common than AD, PD, ALS and HD, their 
severity and impact on society cannot be underestimated.  
 
8. The Therapeutic Implications of Neurodegenerative Disorders 
 
From a neurotherapeutic perspective, it is important to determine whether the early increases in 
neural activity are compensatory or neuropathogenic mechanisms, and to differentiate progression of 
the original neuropathogenic process from the emergence of co-pathogens and the age-related failure 
of compensatory mechanisms [258]. A more comprehensive understanding of the complexities 
encountered with NDs may facilitate the development of superior diagnostic and treatment modalities. 
Although a selection of the current treatments appear to improve the function of remaining neural 
circuits, their effect is limited and none seems capable of a permanent functional rescue [259,260]. 
This suggests that the target strategies employed are too few for the most critical derangements or the 
derangements are too advanced or dynamic for standard regimens [261]. It is also of great interest that 
several disorders, including AD and HD, are associated with an increased incidence of seizures as 
observed in previous studies in transgenic mice, whose neurons express human amyloid precursor 
proteins or mutant huntingtin, were prone to epileptic activity [262-265]. These and other observations 
suggest that the relationship between NDs and epilepsy should be further explored, particularly during 
the early stages and in susceptible sub-populations [38,41]. 
Drugs aimed at neurotransmitter receptors often fail due to signaling pathways that are disrupted by 
abnormal protein assemblies, creating a downstream block that cannot be overcome by upstream 
modulation. Encouragingly, experimental models are helping to unravel the molecular cascades 
through which abnormal protein assemblies may cause disruption [38,266,267]. A pertinent example is 
the recent demonstration that inclusion-body formation in HD does not harm but rather protects 
neurons against the mutant huntingtin protein. A few compensatory mechanisms may result in cell 
survival at the cost of network failure [268]. Thus far, studies have demonstrated that neural plasticity 
may result in a significant, though partial, recovery of neurological function after destruction of an 
important neuronal population [267]. 
Needless to say, is that NDs are chronic, but not static. For example, choline-acetyltransferase 
activity in the hippocampus is increased in mild cognitive impairment, which may precede or represent 
early AD, but is decreased in later stages of the disease raising questions regarding the timing for Int. J. Mol. Sci. 2009, 10                 
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cholinergic-replacement therapy in AD [269,270]. Radiological imaging studies in patients with mild 
cognitive impairment have identified hyperactivation of hippocampal and neocortical regions that 
become hypoactive and atrophic with the progression to AD [271]. Similarly, neuronal activity in the 
globus pallidus appears to be increased during early stages and decreasing in advanced stages of PD. 
To facilitate the development of superior diagnosis and treatment modalities for NDs, these intricacies 
will have to be confronted with diligence. 
 
9. Specialized Drug Delivery Strategies for the Treatment of Neurodegenerative Disorders 
 
Pharmaceutical drug delivery technologies have shown that controlled release of old and new 
neuroactives may decrease the frequency of side-effects [272]. Biodegradable implant technology 
provides a platform for the delivery of neuroactives over several weeks or months in order to 
maneuver the BBB. Such technology is based on the use of bioerodible polymers and excipients, 
which have a proven record of safety and effectiveness in approved drug delivery and medical device 
products. The role of drug delivery technology is significant in the milieu of various therapies for NDs 
including neuroactives in development and the role of unique drug delivery systems. These novel 
methods of drug delivery will have an impact on pharmaceutical and neuro-clinical advancement. In 
their study, Vinogradov and coworkers [273], recommended a novel nanoscale network of crosslinked 
poly(ethylene glycol) and a polyethylenimine nanogel for the delivery of neuroactives such as 
oligonucleotides to the brain. This was an attempt to overcome the challenges posed by the BBB 
restricting the entry of neurotherapeutic molecules and to control drug delivery. Nanogels were able to 
bind and encapsulate spontaneously to negatively charged barriers and formed an aqueous dispersion 
of a polyelectrolyte complex with particle sizes less than 100nm that were transported across the BBB. 
In general, the work hinted at an optimistic future on nano-enabled drug delivery systems to the brain 
for NDs. Rice and coworkers [274], worked on strategies to overcome the p-glycoprotein-mediated 
efflux of paclitaxel (Taxol
®) analogs, which are potential treatments for brain tumors and NDs. 
Biodegradable thermoplastic polymers such as poly(lactic-co-glycolic acid) (PLGA) have been 
used to produce microparticles, for the controlled release of the AD drug, tacrine. Tacrine has a half-
life of 2 – 3 hours, with gastrointestinal, cholinergic, and hepatic side-effects at high doses. The 
controlled drug delivery system was designed to help minimize side-effects by controlling the plasma 
levels of tacrine with sustained delivery [272]. This serves as evidence that polymer engineering by 
manipulating the physical and mechanical strength of polymers may enhance the therapeutic 
effectiveness of neuroactives. 
Tissue engineered devices may also be formed from biodegradable polymers and de-cellularized 
allografts. Cell therapy can be performed where growth factors and neuroactives may be incorporated 
into substrates to encourage cell attachment and function. Stem cells are also a potential therapeutic 
intervention. However, there are numerous controversies with the use of fetal sources of stem cells in a 
few developing countries. Stem cells can be genetically modified prior to transplantation for 
therapeutic interventions in NDs [43,275]. Tissue engineering in the spinal cord has implicated the 
implantation of scaffold material to guide cell placement and foster cell development. The scaffolds 
may also be used to deliver stem cells at the site of interest for enhancement of their regenerative 
potential. At the McEwen Centre for Regenerative Medicine, [276], efforts have been made to develop Int. J. Mol. Sci. 2009, 10                 
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and test various three-dimensional scaffolds in experimental models of spinal cord injury (Figure 7). 
The scaffolds are intended to provide support to replace lost tissue or to act as guidance channels for 
neurons to regenerate beyond the site of injury. Ultimately they could serve as a platform for growth 
factors or neuroprotective drugs.  
Figure 7. A minimally-invasive intrathecal drug delivery system for spinal cord injury 
repair (Source: Shoichet lab, McEwen Centre for Regenerative Medicine, [276]). 
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V1512 is an effervescent drug delivery system being developed for the symptomatic treatment of 
PD. It is a more soluble form of L-dopa comprising methyl ester L-dopa and carbidopa [277]. It is 
envisaged that V1512 will be absorbed more rapidly and consistently than conventional L-dopa 
preparations and thus would offer patients the potential of greater drug efficacy. The clinical efficacy 
and safety of V1512 has been established in a series of studies, which have shown evidence of a 
significantly more rapid onset of action and of reduced 'off' episodes (improved mobility). Clinical 
trials have also demonstrated a more reliable drug response in comparison with conventional L-dopa 
preparations. V1512 is in phase III clinical trials in which the reduction in total daily 'off' episodes will 
be used as a primary endpoint in the pivotal trials. Pharmacokinetic studies comparing plasma levels of 
V1512 with Sinemet
®, a conventional and widely used L-dopa preparation, are also continuing [277]. 
Dopaminergic therapies which include L-dopa and DA-agonists remain the most distinct treatment 
of PD. With the exception of apomorphine injection which is a short-acting DA-agonist, there is no 
other widely available non-oral dopaminergic therapy [278]. Rotigotine is a lipid-soluble, non-ergot, 
D3, D2 and D1 DA-agonist that has demonstrated efficacy as an alternative therapeutic option in both 
early and advanced PD patients [278-280]. More importantly, it is uniquely formulated as a 
transdermal patch system allowing for continuous, once-daily administration and superior patient 
compliance. Preclinical and clinical trials have proven rotigotine to be a well-tolerated and an effective 
treatment for early-stage PD [278,280]. Rotigotine has also shown promise as adjunctive therapy with 
L-dopa for the treatment of advanced PD [279]. The side-effects of rotigotine have been found to be 
similar
 to those of other transdermal systems and DA-agonists [280]. 
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10. Conclusions 
 
AD, PD, ALS and HD are complex neurodegenerative disorders. Their etiology is mostly unknown. 
However severe genetic mutations that lead to miscoding and aggregation in extracellular protein 
depositions have been observed. To date, no completely effective therapies have been developed. 
Research findings that implicate the commonalities in protein aggregations could insinuate that NDs 
share common or overlapping neuropathogenic mechanism(s) which could be targeted by 
synchronized therapeutic strategies. This review provides a model of how the integration of basic 
neuroscience, pharmacology and novel drug delivery technologies may warrant conquering diverse 
approaches for the treatment of NDs. Conceptualizing the molecular basis and neuropathology of NDs 
will offer a worthwhile enlightening understanding of NDs for a broader range of research scientists. 
Furthermore, future studies that will be able to confirm the neuropathogenic significance of reversible 
network dysfunction in NDs may make it possible to shorten clinical trial periods and to evaluate a 
greater diversity of neuroactive compounds. This could accelerate the pace of drug validation and offer 
obvious cost savings. This strategy may also facilitate the identification of effective combinations of 
neuroactives with distinct modes of action. Although such regimens are difficult to assess in clinical 
trials, they have proved useful in other multi-factorial diseases, such as epilepsy, hypertension and 
cancer, and will probably also be required for the effective treatment of NDs. Contemporary findings 
in novel therapeutic targets and treatments, to expose novel trails into drug delivery are also a 
significant part of this challenge. 
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